The promise of scientific and medical innovation often comes with a downside: improvements in care benefit some people, but not all. Without concerted effort, that is exactly what could happen with ...

BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of ...

Published in JCO Precision Oncology, the new analytical validation standards offer an industry-wide protocol for test developersCHICAGO, Jan. 15, 2026 /PRNewswire/ -- A new consensus document ...

Multi-cancer early detection tests (MCEDs), sometimes called liquid biopsy tests, are a new method of detecting cancer early. While the concept is promising, these untested tests currently pose ...

What if a single blood test could determine whether you had one of 14 types of cancer? That's the question posed by a study published in November in the journal Cancer. Conducted by researchers at the ...

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early ...

A blood test based on whole-genome sequencing achieved 99% sensitivity and specificity for detecting HPV-positive head and neck cancer. Early postoperative detection of circulating tumor DNA predicted ...

A blood-based liquid biopsy combining cell-free and exosome-bound microRNAs detected early-onset colorectal cancer (CRC) with strong overall diagnostic performance, high sensitivity for early stages, ...

Among individuals with neurodegenerative diseases, such as Parkinson disease, a skin biopsy test can detect phosphorylated α-synuclein with high accuracy. A high percentage of patients with Parkinson ...

Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies. Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor ...